[Osmoprotection as a new therapeutic principle].
Dry eye syndrome is one of the most common disorders encountered in daily ophthalmological practice. New pathophysiological concepts have been developed over the last few years. Hyperosmolarity of the tear film is one of the key pathogenetic factors in the development of a - commonly subclinical - inflammation of the ocular surface, the lacrimal gland and the tear film in dry eye syndrome. Osmoprotective agents act through compatible solutes to prevent - at least in theory -a hyperosmolar tear film from damaging the ocular surface.
Messmer
E M
EM
Augenklinik, Ludwig-Maximilians-Universität, Mathildenstrasse 8, 80336 München. Elisabeth.Messmer@med.uni-muenchen.de
D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000503:physiopathology*; D005858:Germany; D008954:Models, Biological; D009883:Ophthalmic Solutions / Q000008:administration & dosage*; D010818:Practice Patterns, Physicians' / Q000639:trends*; D013666:Tears / Q000378:metabolism*; D014882:Water-Electrolyte Balance / Q000187:drug effects*
D009883:Ophthalmic Solutions